Capmatinib Safety for Cancer
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it seems that participants must already be receiving capmatinib treatment or a combination treatment to join the study.
What data supports the effectiveness of the drug Capmatinib for cancer?
Capmatinib has shown effectiveness in treating lung cancer with a specific genetic mutation (MET exon 14 skipping) by inhibiting cancer cell growth, as demonstrated in clinical studies. It has been approved for use in the USA for this type of lung cancer, and ongoing research is exploring its potential for other cancers.12345
Is Capmatinib safe for humans?
Capmatinib has been studied for safety in humans, with some patients experiencing side effects like nausea, vomiting, and increased blood creatinine (a waste product in the blood). Serious side effects can include lung disease, liver toxicity, and depression, but the maximum safe dose was not reached in studies, indicating it may be generally safe at certain doses.13467
How is the drug Capmatinib different from other cancer treatments?
Capmatinib is unique because it is an oral drug that specifically targets and inhibits the MET protein, which is involved in cancer cell growth, especially in cases with a specific mutation called MET exon 14 skipping. This makes it particularly effective for certain types of lung cancer, and it is being explored for use in other cancers as well.14689
Research Team
Toni Wozniak, MD
Principal Investigator
Barbara Ann Karmanos Cancer Institute
Eligibility Criteria
This trial is for patients who are already part of a Novartis study and benefit from continuing Capmatinib alone or with other treatments. It's not for pregnant women, those able to become pregnant without effective contraception, or anyone receiving live vaccines recently.Inclusion Criteria
Exclusion Criteria
Timeline
Treatment
Participants continue receiving capmatinib treatment as monotherapy or in combination with other treatments
Safety Assessment
Safety assessment including adverse events and serious adverse events collection, local laboratory test monitoring, and local standard of care assessments
Follow-up
Participants are monitored for safety for 30 days after the last dose of study treatment or until SAE is resolved
Treatment Details
Interventions
- Capmatinib
- Gefitinib
- Nazartinib
- Osimertinib
Capmatinib is already approved in United States, European Union, Canada for the following indications:
- Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping
- Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping
- Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD